Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study
Roger J. Laham(Beth Israel Deaconess Medical Center), Michael Simons(Yale University), Mark E. Leimbach(Emory University), Roderic I. Pettigrew(Biotex (United States)), Carl Yoshizawa(Einstein Medical Center Philadelphia), M.J. Whitehouse(Dartmouth–Hitchcock Medical Center), James E. Udelson(Tufts Medical Center), Justin D. Pearlman(Dartmouth College), Marilyn C. Pike(Bethesda Hospital), Nicholas Chronos(Atlanta Gastroenterology Associates)
Cited by 223
Related Papers
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Journal of the American College of Cardiology|2011|1.3k
Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
|Circulation|2014|1k